Safety and efficacy of nivolumab therapy in patients with metastatic renal cell carcinoma and impaired kidney function-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and efficacy of nivolumab therapy in patients with metastatic renal cell carcinoma and impaired kidney function

Published:2024-05 Issue:4 Volume:48 Page:273-280
ISSN:2173-5786
Container-title:Actas Urológicas Españolas (English Edition)
language:en
Short-container-title:Actas Urológicas Españolas (English Edition)

Author:

Sengul N.,Gültürk I.,Yilmaz M.,Celik E.,Paksoy N.,Yekedüz E.,Ürün Y.,Basaran M.,Özgüroğlu M.

Publisher

Elsevier BV

Reference23 articles.

1. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

2. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates;Wang;Cancer Immunol Res,2014

3. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015

4. Renal Insufficiency and Cancer Medications (IRMA) STUDY GROUP. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study;Launay-Vacher;Cancer,2007

5. New model for estimating glomerular filtration rate in patients with cancer;Janowitz;J Clin Oncol,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP